NEW YORK (GenomeWeb News) – UK molecular diagnostics firm Lumora today announced a licensing deal to develop tests for veterinary diagnostics company Biogal Galed Labs.

The deal provides Israel-based Biogal access to Lumora's technologies, including BART, or Bioluminescent Assay in Real Time, as well as its expertise in test development, reader technologies, and manufacturing, Lumora said. Initially, Lumora will develop a test for leptospirosis, a zoonotic bacterial infection that is transmitted through urine.

Development of other tests is expected to follow.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.